§1320a-7b(f)) (c) disqualified by any government or regulatory agencies from performing specific services, and is not subject to a pending disqualification proceeding or (d) convicted of a criminal offense related to the provision of health care items or services, or under investigation or subject to any such action that is pending.Ģ. §335a (b) excluded, debarred or suspended from, or otherwise ineligible to participate in, any federal or state health care program or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. The Consultant represents and warrants that he has not been, and is not under consideration to be: (a) debarred from providing services pursuant to Section 306 of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. The Consultant agrees to provide the Consulting Services to the Company in accordance with all applicable laws and regulations and the highest professional standards. The total number of hours of services to be provided by the Consultant during the Consultation Period (as defined below) shall not exceed twenty percent (20%) of the total number of hours of services that the Consultant provided in a thirty six-month period as an employee of the Company immediately prior to the Effective Date.ġ.2 Performance. In the role of senior advisor to the Company, the Consultant agrees to provide such advisory services to the Company (including without limitation through meetings with members of its senior management) as described in more detail in Exhibit A hereto, which are anticipated not to exceed sixteen (16) hours per month on average (“ Consulting Services”). NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties agree as follows:ġ.1 Consulting Services. WHEREAS, the Company and the Consultant desire to establish the terms and conditions under which the Consultant shall provide advisory services to the Company WHEREAS, the Consultant is a highly experienced biotechnology executive with prior experience developing and leading commercial teams and launching products and WHEREAS, the Consultant continues to serve as Chairman of the Board and WHEREAS, the Consultant’s employment with the Company ended on the Employment Termination Date and WHEREAS, the Consultant is a member of the Board of Directors (the “ Board”) of the Company and also served as a part time employee of the Company with the title Executive Chairman until December 31, 2022 pursuant to an Amended and Restated Employment Agreement effective as of April 4, 2022 by and between the Company and the Consultant (the “ Employment Agreement”) that expired on December 31, 2022 (the “ Employment Termination Date”) by its terms and THIS CONSULTING AGREEMENT (this “ Agreement”), made effective as of the 1 st day of January, 2023 (the “ Effective Date”), is entered into by and between Blueprint Medicines Corporation, a Delaware corporation (the “ Company”), and Jeffrey W. For more information, visit and follow us on Twitter and LinkedIn.EX-10.1 2 tm2233493d1_ex10-1.htm EXHIBIT 10.1 Today, we have brought our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for mast cell disorders, including systemic mastocytosis and chronic urticaria, breast cancer and other cancers vulnerable to CDK2 inhibition, as well as EGFR-mutant lung cancer. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.īlueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. ET.Ī live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at. 28, 2023 /PRNewswire/ - Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, Decemat 11:00 a.m.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |